港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

485.171

+2.8150.58%

漲家數：21

跌家數：10

平家數：2

市盈率：- -

高：489.931

開：482.072

低：481.405

收：482.357

成交量：6,161.09萬

成交額：12.82億

市值：3,079.80億

流通市值：2,738.27億

資料載入中...

總覽新聞資訊

研報掘金丨中金：下調康方生物目標價至120港元，維持「跑贏行業」評級

連虧7年半股迪哲醫藥董事長擬減持 A股募資39億零派息

《大行》大和：康方生物(09926.HK) HARMONi-2中期OS分析達標略增全球一線NSCLC III期試驗OS成功信心

阿斯达克财经

基石藥業－Ｂ(02616)股價上升5.016%，現價港幣$6.49

阿斯达克财经

創新藥板塊活躍昂利康漲停

更多創新藥有望納入醫保報銷

康方生物盤中升逾8% 康方生物依沃西與K藥頭對頭研究獲顯著陽性結果

康方生物(09926)出現大手買入5.5萬股，成交價$98.0，涉資539萬

阿斯达克财经

港股異動 | 康方生物(09926)早盤升逾10% 康方生物依沃西與K藥頭對頭研究獲顯著陽性結果

中生製藥(01177.HK)GPC3 ADC臨床試驗申請獲FDA批准

阿斯达克财经

勁方醫藥-B(02595)存倉市值總計19.55億港元股東將4373.09萬股股票存入渣打銀行(香港)

醫藥代表退場，基藥目錄「及時雨」能否解藥企之渴？

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BK1574/news?page=17"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":485.17123,"timestamp":1789632487194,"preClose":482.35672,"halted":0,"volume":61610930,"delay":0,"changeRate":0.005835,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":2.814514,"latestTime":"09-17 16:00:00","open":482.07187,"high":489.93134,"low":481.40475,"amount":1281540013.5,"amplitude":0.017677,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789695000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789608600000,1789617600000],[1789621200000,1789632000000]],"pbRate":3.604829,"peRate":160.310337,"turnoverRate":0.002293,"increases":18,"decrements":10,"flats":4,"marketCap":307980316848,"floatMarketCap":273827471128},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":489.93134,"amplitude":0.017677,"preClose":482.35672,"low":481.40475,"pbRate":"3.604829","latestPrice":485.17123,"volume":61610930,"delay":0,"open":482.07187,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":496.758,"twentyDayClose":517.015,"sixtyDayClose":440.071,"secType":"PLATE","market":"HK","turnoverRate":0.002293,"peRate":160.310337,"marketCap":307980316848,"floatMarketCap":273827471128,"timestamp":1789632487194,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":21,"down":10,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:17,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664389264","title":"研報掘金丨中金：下調康方生物目標價至120港元，維持「跑贏行業」評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2664389264","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664389264?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 13:33","pubTimestamp":1788499992,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00B5MMRT66.SGD","KURE","LU2399975544.HKD","LU0348825331.USD","LU1961090484.USD","LU1794554557.SGD","09926","LU0348784397.USD","LU2476274720.SGD","LU1720050803.USD","IE00B543WZ88.USD","LU0348767384.USD","LU0348735423.USD","LU0417516738.SGD","LU0540923850.HKD","LU2476274308.USD","LU0348783233.USD","BK1161","IE00BPRC5H50.USD","BK1574","LU2488822045.USD","LU0417516902.SGD","LU2778985437.USD","LU0561508036.HKD","LU0348766576.USD","LU0634319403.HKD","LU0417516571.SGD","LU0348827113.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664138500","title":"連虧7年半股迪哲醫藥董事長擬減持 A股募資39億零派息","url":"https://stock-news.laohu8.com/highlight/detail?id=2664138500","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664138500?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 11:34","pubTimestamp":1788492846,"startTime":"0","endTime":"0","summary":"中国经济网北京9月4日讯 迪哲医药 昨日晚间发布关于董事、高级管理人员减持股份计划公告。　　迪哲医药称，上述减持对象本次减持数量占其本人本次减持前所持有公司股份数量均不超过25%。　　截至减持股份计划预披露公告发布前最后一个交易日，即2026年9月3日，迪哲医药收报60.08元，以此计算，上述减持主体本次减持金额合计预计为2.17亿元。　　经计算，迪哲医药上述两次募集资金金额合计为38.99亿元。　　迪哲医药自上市以来未分红。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260904/32360003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02827","399300","82846","BK4588","BK1161","03188","159982","BK1515","VIG","09939","BK1147","BK4585","02846","BK1574","03130","07233","83130","159938","83188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664385068","title":"《大行》大和：康方生物(09926.HK) HARMONi-2中期OS分析達標 略增全球一線NSCLC III期試驗OS成功信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2664385068","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664385068?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 11:22","pubTimestamp":1788492120,"startTime":"0","endTime":"0","summary":"大和发表研报指，康方生物依沃西一线治疗PD-L1表达阳性 NSCLC三期研究，经独立数据监察委员会评估的预设总生存期期中分析显示，研究达到OS关键次要终点。大和认为，此进一步验证依沃西单抗在一线NSCLC的OS临床获益，成功由强劲的无进展生存期临床获益转化而来。公司先前亦公布早期中期OS HR为0.777。虽然本次中期OS分析的详细数据尚未公布，但大和认为有助于略为提高对其全球一线NSCLC三期试验OS成功的信心，对康方生物评级为“买入”。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230531145638513_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230531145638513_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1542938/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1542938/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2488822045.USD","09926","LU0348825331.USD","KURE","IE00BPRC5H50.USD","LU0417516738.SGD","LU0540923850.HKD","LU2778985437.USD","LU0348784397.USD","LU0417516571.SGD","LU2476274308.USD","LU1720050803.USD","IE00B5MMRT66.SGD","LU0348735423.USD","BK1161","LU2399975544.HKD","LU0348766576.USD","LU0348767384.USD","LU0348827113.USD","LU1794554557.SGD","LU1961090484.USD","LU0561508036.HKD","BK1574","LU2476274720.SGD","LU0417516902.SGD","LU0348783233.USD","IE00B543WZ88.USD","LU0634319403.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664852713","title":"基石藥業－Ｂ(02616)股價上升5.016%，現價港幣$6.49","url":"https://stock-news.laohu8.com/highlight/detail?id=2664852713","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664852713?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 11:09","pubTimestamp":1788491340,"startTime":"0","endTime":"0","summary":"[上升股]基石药业－Ｂ(02616) 股价在上午11:08比前收市价上升5.016%，现股价为港币$6.49。至目前为止，今日最高价为$6.49，而最低价为$6.2。总成交量为307.65万股，总成交金额为港币$1.964千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609045563/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609045563/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","02616","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664385956","title":"創新藥板塊活躍 昂利康漲停","url":"https://stock-news.laohu8.com/highlight/detail?id=2664385956","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664385956?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 10:57","pubTimestamp":1788490620,"startTime":"0","endTime":"0","summary":"上证报中国证券网讯(记者冯心怡)9月4日早盘，创新药板块表现活跃，昂利康涨停，报27.86元/股，涨幅为9.99%。昂利康坚持“仿制药—改良型新药—创新药”的研发布局。据新华社9月4日消息，国 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260904/c679599107.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260904/c679599107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["159992","IBBQ","BK1161","MEDX","LNGR","BK0239","002940","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664383252","title":"更多創新藥有望納入醫保報銷","url":"https://stock-news.laohu8.com/highlight/detail?id=2664383252","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664383252?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 10:20","pubTimestamp":1788488426,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","ENTL","HART","IBBQ","IHI","LNGR","MEDX","06978","PSCH","159992","BK1161","BK1574","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664383605","title":"康方生物盤中升逾8% 康方生物依沃西與K藥頭對頭研究獲顯著陽性結果","url":"https://stock-news.laohu8.com/highlight/detail?id=2664383605","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664383605?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 10:02","pubTimestamp":1788487320,"startTime":"0","endTime":"0","summary":"9月4日，$康方生物$盘中涨超8%。9月3日，康方生物宣布，依沃西单抗头对头对比$K$药一线治疗PD-L1阳性晚期非小细胞肺癌的三期临床HARMONi-2达到OS关键次要终点，取得具有统计学显著性和临床获益的阳性结果。截至目前，依沃西已在多项头对头对比PD-1/L1疗法的全球Ⅲ期临床中，取得OS和PFS双阳性结果，未来有望凭借更优疗效撬动既有市场格局。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-04/doc-iniqrpqw4027860.shtml","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2476274308.USD","LU1794554557.SGD","LU0348767384.USD","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU1961090484.USD","BK1574","LU2488822045.USD","LU0348783233.USD","LU2399975544.HKD","LU0348766576.USD","LU0540923850.HKD","LU0348827113.USD","IE00B5MMRT66.SGD","LU0417516902.SGD","09926","LU2476274720.SGD","KURE","LU0348825331.USD","LU0348784397.USD","LU0417516738.SGD","LU1720050803.USD","LU2778985437.USD","LU0348735423.USD","LU0417516571.SGD","LU0561508036.HKD","BK1161","LU0634319403.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664831303","title":"康方生物(09926)出現大手買入5.5萬股，成交價$98.0，涉資539萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2664831303","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664831303?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 10:00","pubTimestamp":1788487200,"startTime":"0","endTime":"0","summary":"[大手成交]康方生物(09926)在上午10:00出现大手买入，成交量为5.5万，成交价为港币$98.0，涉资539万。至目前为止，股价升7.819%，今日最高价为$100.3，而最低价为$94.6，总成交量为1.16千万股，总成交金额港币$11.407亿。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609043591/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609043591/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1961090484.USD","BK1161","LU0348767384.USD","LU2778985437.USD","IE00BPRC5H50.USD","LU0634319403.HKD","LU2476274720.SGD","LU2476274308.USD","LU2488822045.USD","LU0348783233.USD","LU1720050803.USD","LU1794554557.SGD","LU0348766576.USD","LU0348735423.USD","KURE","LU0540923850.HKD","09926","LU0561508036.HKD","BK1574","LU0417516571.SGD","IE00B5MMRT66.SGD","LU0348784397.USD","LU0348825331.USD","LU2399975544.HKD","IE00B543WZ88.USD","LU0348827113.USD","LU0417516738.SGD","LU0417516902.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664887233","title":"港股異動 | 康方生物(09926)早盤升逾10% 康方生物依沃西與K藥頭對頭研究獲顯著陽性結果","url":"https://stock-news.laohu8.com/highlight/detail?id=2664887233","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664887233?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 09:35","pubTimestamp":1788485751,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物早盘涨超10%。消息面上，9月3日，康方生物宣布，依沃西单抗头对头对比K药一线治疗PD-L1阳性晚期非小细胞肺癌的三期临床HARMONi-2达到OS关键次要终点，取得具有统计学显著性和临床获益的阳性结果。截至目前，依沃西已在多项头对头对比PD-1/L1疗法的全球Ⅲ期临床中，取得OS和PFS双阳性结果，未来有望凭借更优疗效撬动既有市场格局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491892.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2778985437.USD","BK1574","LU0348735423.USD","KURE","LU0417516571.SGD","LU0417516738.SGD","LU0348825331.USD","LU2476274308.USD","LU0348783233.USD","LU0561508036.HKD","LU0348784397.USD","LU0417516902.SGD","LU2488822045.USD","09926","BK1161","LU0634319403.HKD","LU2399975544.HKD","IE00B5MMRT66.SGD","LU0348766576.USD","LU0348827113.USD","LU1961090484.USD","IE00BPRC5H50.USD","LU2476274720.SGD","LU1720050803.USD","LU1794554557.SGD","LU0540923850.HKD","IE00B543WZ88.USD","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664241388","title":"中生製藥(01177.HK)GPC3 ADC臨床試驗申請獲FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664241388","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664241388?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 09:24","pubTimestamp":1788485040,"startTime":"0","endTime":"0","summary":"中国生物制药(01177.HK) 公布，集团附属公司正大天晴自主研发的国家1类新药TQB6426“GPC3抗体药物偶联物(ADC)”已获得美国食品药品监督管理局(FDA)的新药临床试验(IND)批准，拟用于晚期恶性肿瘤。目前，全球尚无靶向GPC3的ADC药物获批上市，同类候选产品整体处于临床前及早期临床探索阶段。集团将加速TQB6426的I期临床试验，评估其在晚期恶性肿瘤患者中的安全性、耐受性、药代动力学特征及初步疗效，尽早为全球肝细胞癌及更多实体瘤患者提供新的治疗选择。(sl/a)(港股报价延迟最少十五分钟。沽空资料截至 2026-09-03 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1542877/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1542877/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["HK0000165453.HKD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1191","BK1515","BK1589","BK1521","01477","01177","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664388377","title":"勁方醫藥-B(02595)存倉市值總計19.55億港元 股東將4373.09萬股股票存入渣打銀行(香港)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664388377","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664388377?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 08:34","pubTimestamp":1788482051,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，9月3日，劲方医药-B(02595)出现存仓异动，存仓市值总计19.55亿港元，占比19.65%。该公司股东将4373.09万股股票存入渣打银行(香港)，持股比例增加12.44%。劲方医药此前发布公告，GFH375已进入一线治疗KRAS G12D突变型晚期非小细胞肺癌(NSCLC)的II期研究，包括单药疗法、联合EGFR单抗(西妥昔单抗)或联合化疗(培美曲塞)三种治疗方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK1515","02595","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664803502","title":"醫藥代表退場，基藥目錄「及時雨」能否解藥企之渴？","url":"https://stock-news.laohu8.com/highlight/detail?id=2664803502","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664803502?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 23:41","pubTimestamp":1788450086,"startTime":"0","endTime":"0","summary":"02 8年磨一剑，基药目录送来“及时雨”恰在此时，基药目录更新了。二是基药目录首次纳入创新药。集采中标、医保谈判、基药目录入围构成了药品放量的三大政策通道。白马认为，基药目录的“及时雨”能解药企一时之渴，却解不了长期之渴。当医药代表退场的尘埃落定，当“带金销售”彻底成为过去式，真正能笑到最后的，是那些产品过硬、证据扎实、推广合规的药企。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788329362059116704","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["159938","BK1515","09939","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":17,"totalSize":332,"code":"91000000","status":"200"}]}}